Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Atezolizumab
Related studies linked through entity extraction aliases.
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
- Status
- TERMINATED
- Phase
- PHASE2
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
- Status
- COMPLETED
- Phase
- PHASE2
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- Status
- RECRUITING
- Phase
- PHASE2